iRhythm Technologies (NASDAQ:IRTC) Sees Strong Trading Volume on Strong Earnings

iRhythm Technologies (NASDAQ:IRTC) saw unusually-strong trading volume on Friday after the company announced better than expected quarterly earnings. 528,408 shares were traded during mid-day trading, a decline of 13% from the previous session’s volume of 604,272 shares.The stock last traded at $130.9950 and had previously closed at $128.12.

The company reported $0.58 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.62. The business had revenue of $224.17 million during the quarter, compared to the consensus estimate of $219.30 million. iRhythm Technologies had a negative net margin of 3.53% and a negative return on equity of 10.26%. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.32) earnings per share.

Key Headlines Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q2 results beat expectations: iRhythm reported earnings of $0.58 per share versus the consensus estimate of a $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding estimates of $219.30 million. The improvement compares with a $0.32-per-share loss in the prior-year quarter. iRhythm Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VitalConnect acquisition expands the platform: iRhythm agreed to acquire VitalConnect for $287.5 million, adding monitoring capabilities across ambulatory, inpatient and hospital-to-home care. Management expects the transaction to close by year-end, potentially expanding its addressable market and product portfolio. iRhythm to Buy VitalConnect for $287.5M
• Positive Sentiment: Full-year outlook remains solid: iRhythm forecast 2026 revenue of $880 million to $890 million, broadly in line with the roughly $881.3 million analyst consensus, and targeted a 13% to 14% adjusted EBITDA margin. The guidance reinforces expectations for continued growth and improving operating leverage. iRhythm Outlines 2026 Revenue Outlook
• Neutral Sentiment: Legal overhang addressed: A proposed class-action settlement for purchasers of iRhythm common stock received court approval, potentially reducing litigation uncertainty, although the announcement did not specify the settlement’s financial impact. Proposed iRhythm Class Action Settlement
• Negative Sentiment: Profitability and execution remain concerns: Despite the quarterly EPS surprise, iRhythm still reported a negative net margin and negative return on equity. Investors will also monitor the cost, integration and execution risks associated with the VitalConnect transaction.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on IRTC shares. Wells Fargo & Company cut their price objective on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Bank of America dropped their target price on iRhythm Technologies from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. The Goldman Sachs Group cut their price target on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Needham & Company LLC reduced their price target on shares of iRhythm Technologies from $255.00 to $192.00 and set a “buy” rating for the company in a research report on Friday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of iRhythm Technologies from $215.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, iRhythm Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $180.21.

Insider Activity

In related news, Director Abhijit Y. Talwalkar bought 5,312 shares of the stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $10.71 per share, for a total transaction of $56,891.52. Following the completion of the purchase, the director directly owned 25,611 shares of the company’s stock, valued at $274,293.81. This represents a 26.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IRTC. Measured Wealth Private Client Group LLC purchased a new stake in iRhythm Technologies in the 3rd quarter worth approximately $30,000. Employees Retirement System of Texas purchased a new position in shares of iRhythm Technologies during the 3rd quarter valued at approximately $36,000. Harbor Investment Advisory LLC acquired a new position in shares of iRhythm Technologies in the 2nd quarter valued at $50,000. Torren Management LLC acquired a new position in shares of iRhythm Technologies in the 4th quarter valued at $53,000. Finally, Smartleaf Asset Management LLC boosted its holdings in iRhythm Technologies by 63.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 323 shares of the company’s stock worth $58,000 after buying an additional 125 shares in the last quarter.

iRhythm Technologies Price Performance

The stock has a market capitalization of $4.28 billion, a PE ratio of -152.96 and a beta of 1.30. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98. The stock’s fifty day moving average is $114.76 and its 200-day moving average is $124.55.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.